411 related articles for article (PubMed ID: 11796397)
1. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
Dick T; Mierau R; Bartz-Bazzanella P; Alavi M; Stoyanova-Scholz M; Kindler J; Genth E
Ann Rheum Dis; 2002 Feb; 61(2):121-7. PubMed ID: 11796397
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
[TBL] [Abstract][Full Text] [Related]
3. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
4. Bibliographical study of the concurrent existence of anticentromere and antitopoisomerase I antibodies.
Kikuchi M; Inagaki T
Clin Rheumatol; 2000; 19(6):435-41. PubMed ID: 11147751
[TBL] [Abstract][Full Text] [Related]
5. Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.
Vázquez-Abad D; Grodzicky T; Senécal JL
Clin Immunol; 1999 Feb; 90(2):182-9. PubMed ID: 10080829
[TBL] [Abstract][Full Text] [Related]
6. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies.
Sato S; Ihn H; Soma Y; Shimozuma M; Shishiba T; Takehara K
J Rheumatol; 1993 Nov; 20(11):1961-3. PubMed ID: 8308786
[TBL] [Abstract][Full Text] [Related]
7. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies.
Falkner D; Wilson J; Medsger TA; Morel PA
Arthritis Rheum; 1998 Jan; 41(1):74-80. PubMed ID: 9433872
[TBL] [Abstract][Full Text] [Related]
8. Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma.
Satoh M; Akizuki M; Kuwana M; Mimori T; Yamagata H; Yoshida S; Homma M; Yamamoto T; Sasazuki T
J Rheumatol; 1994 Jan; 21(1):111-4. PubMed ID: 8151564
[TBL] [Abstract][Full Text] [Related]
9. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
[TBL] [Abstract][Full Text] [Related]
10. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features of systemic sclerosis and association with antitopoisomerase-1 antibody and centromere pattern of antinuclear antibody].
Bertazzi GR; de Toledo RA; de Godoy MF; Geraldino GC; Polizelli DV; Fernandes GC; Pedroso CL; dos Santos FG; de Assis TM
Acta Reumatol Port; 2012; 37(1):9-17. PubMed ID: 22781510
[TBL] [Abstract][Full Text] [Related]
12. Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis.
Bournia VK; Diamanti KD; Vlachoyiannopoulos PG; Moutsopoulos HM
Arthritis Res Ther; 2010; 12(2):R47. PubMed ID: 20302639
[TBL] [Abstract][Full Text] [Related]
13. Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis.
Kuwana M; Inoko H; Kameda H; Nojima T; Sato S; Nakamura K; Ogasawara T; Hirakata M; Ohosone Y; Kaburaki J; Okano Y; Mimori T
Intern Med; 1999 Apr; 38(4):336-44. PubMed ID: 10361906
[TBL] [Abstract][Full Text] [Related]
14. Antitopoisomerase 1 antibodies in systemic sclerosis: how to improve the detection?
Tamby MC; Bussone G; Mouthon L
Ann N Y Acad Sci; 2007 Aug; 1109():221-8. PubMed ID: 17785309
[TBL] [Abstract][Full Text] [Related]
15. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.
Weiner ES; Earnshaw WC; Senécal JL; Bordwell B; Johnson P; Rothfield NF
Arthritis Rheum; 1988 Mar; 31(3):378-85. PubMed ID: 2833902
[TBL] [Abstract][Full Text] [Related]
16. The value of pattern capillary changes and antibodies to predict the development of systemic sclerosis in patients with primary Raynaud's phenomenon.
Pavlov-Dolijanovic SR; Damjanov NS; Vujasinovic Stupar NZ; Baltic S; Babic DD
Rheumatol Int; 2013 Dec; 33(12):2967-73. PubMed ID: 23934522
[TBL] [Abstract][Full Text] [Related]
17. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
[TBL] [Abstract][Full Text] [Related]
18. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
Coelho Horimoto AM; da Costa IP
Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies in systemic sclerosis.
Vázquez-Abad D; Rothfield NF
Int Rev Immunol; 1995; 12(2-4):145-57. PubMed ID: 7650418
[TBL] [Abstract][Full Text] [Related]
20. Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody.
Komura K; Yanaba K; Ogawa F; Shimizu K; Takehara K; Sato S
Clin Exp Dermatol; 2008 May; 33(3):329-32. PubMed ID: 18312458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
